Published in J Neural Transm (Vienna) on September 25, 2012
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol (2016) 0.94
Diagnosis and treatment of dystonia. Neurol Clin (2015) 0.90
Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics (2014) 0.88
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
'Similar to' is not 'identical with', and 'identical with' is not 'the same as'. Drugs R D (2015) 0.84
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D (2015) 0.84
Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm (Vienna) (2013) 0.79
Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem (2014) 0.77
Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice. J Immunol (2015) 0.77
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J (2014) 0.75
Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. Cell Immunol (2017) 0.75
Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors. Sci Rep (2015) 0.75
Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol (2016) 0.75
Botulinum Toxin Off-Label Use in Dermatology: A Review. Skin Appendage Disord (2017) 0.75
Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurol Sci (2017) 0.75
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med (2002) 5.34
Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol (2010) 2.68
Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet (1977) 2.60
Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev (1992) 2.60
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol (2011) 2.37
Structural basis of TLR5-flagellin recognition and signaling. Science (2012) 2.10
Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology (1993) 2.02
Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology (2005) 1.99
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna) (2005) 1.97
Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord (1994) 1.88
Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun (1996) 1.82
Botulinum toxin treatment of spasmodic torticollis. J R Soc Med (1992) 1.81
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord (2002) 1.79
Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol (2009) 1.65
Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J (2008) 1.63
Basic immunological aspects of botulinum toxin therapy. Mov Disord (2004) 1.62
Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science (2012) 1.62
Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol (1997) 1.61
Purification and amino acid composition of type A botulinum neurotoxin. Toxicon (1984) 1.61
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology (2003) 1.50
Serum antibody production to botulinum A toxin. Ophthalmology (1993) 1.49
Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol (1992) 1.47
Response and immunoresistance to botulinum toxin injections. Neurology (1995) 1.35
Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immun (1976) 1.34
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol (2001) 1.34
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics (2010) 1.33
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol (1999) 1.26
Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol (2009) 1.26
Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol (2007) 1.19
Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun (1997) 1.15
Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord (2010) 1.15
Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil (2008) 1.12
Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol (2009) 1.10
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines. J Clin Aesthet Dermatol (2011) 1.08
Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins. Curr Microbiol (1994) 1.08
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol (2007) 1.07
Therapeutic use of botulinum toxins: background and history. Clin J Pain (2003) 1.06
Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology (1998) 1.02
Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord (2005) 1.00
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol (2006) 1.00
Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.98
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther (2007) 0.98
The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord (1997) 0.97
Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord (2004) 0.96
Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol (2006) 0.96
Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord (2005) 0.96
Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol (1995) 0.95
Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. Mol Pharm (2007) 0.95
Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil (2004) 0.95
Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm (Vienna) (2009) 0.94
Clinical correlates of response to botulinum toxin injections. Arch Neurol (1991) 0.93
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry (1999) 0.93
A double blind trial of botulinum toxin "A" in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry (1991) 0.91
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther (2005) 0.91
Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon (2009) 0.89
Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology (2004) 0.88
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol (2003) 0.88
The biochemistry of botulinum toxin type B. Neurology (2000) 0.88
The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry (2004) 0.87
Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E. Biochemistry (2007) 0.87
Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm (2008) 0.86
Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur Urol (2010) 0.86
On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology (2006) 0.86
Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol (2005) 0.86
Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg (2009) 0.85
Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int (2009) 0.85
Phase I comparability of recombinant human albumin and human serum albumin. J Clin Pharmacol (2005) 0.84
An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol (2009) 0.84
Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res (2006) 0.84
Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody. Infect Immun (1989) 0.84
Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol (2004) 0.83
Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol (2009) 0.82
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology (2006) 0.82
Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest (2002) 0.82
An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J (2009) 0.81
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol (2008) 0.81
Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. Neuroscience (2011) 0.80
The protein load of therapeutic botulinum toxins. Eur J Neurol (2007) 0.80
Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol (2002) 0.80
Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox. Isr Med Assoc J (2008) 0.80
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology (2010) 0.79
Xeomin in the treatment of cervical dystonia. Eur J Neurol (2009) 0.79
The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol (2000) 0.78
Botulinum toxin type A in refractory chronic migraine: an open-label trial. Arq Neuropsiquiatr (2007) 0.78
Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol (2001) 0.77
Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A (2002) 2.14
Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res (2009) 1.73
Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment. Dermatol Surg (2015) 1.52
Analysis of the neurogenic potential of multipotent skin-derived precursors. Exp Neurol (2006) 1.44
SMAP-29 has two LPS-binding sites and a central hinge. Eur J Biochem (2002) 1.13
Differential frequency dependence of P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes. J Neurosci (2003) 1.08
Heterogeneity of crow's feet line patterns in clinical trial subjects. Dermatol Surg (2015) 0.87
Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatol Surg (2015) 0.83
Safety of the open-irrigated ablation catheter for radiofrequency ablation: safety analysis from six clinical studies. Pacing Clin Electrophysiol (2012) 0.83
Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments. Dermatol Surg (2015) 0.80
Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials. Dermatol Surg (2016) 0.77
The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina. Aesthet Surg J (2013) 0.76
Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg (2013) 0.76
The Efficacy and Safety of Topical Dapsone Gel, 5% for the Treatment of Acne Vulgaris in Adult Females With Skin of Color. J Drugs Dermatol (2016) 0.75
Facial Treatment Preferences Among Aesthetically Oriented Men. Dermatol Surg (2016) 0.75
A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study. Dermatol Surg (2016) 0.75
Signs of Facial Aging in Men in a Diverse, Multinational Study: Timing and Preventive Behaviors. Dermatol Surg (2017) 0.75
A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Dermatol Surg (2014) 0.75
HYC-24L Demonstrates Greater Effectiveness With Less Pain Than CPM-22.5 for Treatment of Perioral Lines in a Randomized Controlled Trial. Dermatol Surg (2015) 0.75